BioSpace News Archive

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve System, announced highlights from PCR London Valves 2023, a leading, annual global valve conference.

Scilex Holding Company announced that one Midwestern and one Southern State voted to add ZTlido® as a preferred agent to their Medicaid Preferred Drug Lists effective as of January 1, 2024.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting 3 posters including two today at the 2023 San Antonio Breast Cancer Symposium® at Henry B. Gonzalez Convention Center, San Antonio, TX.

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure.

BriaCell Therapeutics Corp. is thrilled to announce continued outstanding topline survival and clinical benefit data in advanced metastatic breast cancer patients treated Bria-IMT™ in combination with an immune check point inhibitor (CPI).

LTS, a leading pharmaceutical technology company, announced that it has received a grant from the Bill & Melinda Gates Foundation.

Mosie Baby, a pioneering at-home fertility care company, has secured FDA Class II clearance for its Mosie Baby Kit making it the first and only FDA-cleared over-the-counter kit for use in intravaginal insemination (IVI).

Kubota Vision Inc., a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced the execution of a vendor agreement between Kubota Vision and IQVIA Services Japan G.K. for eyeMO, a portable, low-cost, home-based, remote and in-office ophthalmic OCT*1 device for monitoring of retinal diseases.

Autonomix Medical, Inc. (“Autonomix” or the “Company”) today announced that it will present at the Virtual Investor: A Breakthrough Medical Device for the Diagnosis and Treatment of Diseases of the Nervous System event on Monday, December 11, 2023 at 2:00 PM ET.

Compass Pathways plc announced the publication of a paper in JAMA Psychiatry that demonstrates the potential for investigational COMP360 psilocybin treatment in treatment-resistant bipolar type II disorder.